Article Menu

Export Article

EndNote (RIS)
BibTeX
RefMan
RefWorks

Article Data

Views 263
Dowloads 125

Original Research

Open Access

Interval debulking in epithelial ovarian carcinomas: the past, present and the future

M. Gultekin^1,*,
K. Diribas¹
E. Buru¹
P. Dursun²
K. Yuce³
A. Ayhan²

¹Department of Obstetrics and Gynecology, Cankiri Government Hospital, Cankiri, Turkey

²Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Baskent University School of Medicine, Maltepe, Ankara, Turkey

³Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey

DOI: 10.12892/ejgo200803242 Vol.29,Issue 3,May 2008 pp.242-245

Published: 10 May 2008

*Corresponding Author(s): M. Gultekin E-mail: mrtgultekin@yahoo.com

PDF (66.33 kB)

Abstract

Primary cytoreductive surgery followed by combination chemotherapy of paclitaxel and cisplatinum is the standard treatment for advanced staged epithelial ovarian cancers. Despite the maximal efforts to increase optimal cytoreductive success rates and related ultra-radical surgeries, five-year survival rates are still poor. Primary cytoreductive surgeries and their radicalities have been criticized since the early nineties. Interval debulking surgery (IDS) and neo-adjuvant chemotherapy (NAC) are the two suggested alternatives to the primary debulking approaches. In this article, the authors summarize and discuss the IDS approach with an associated literature review.

Keywords

Interval debulking surgery; Interval laparotomy; Epithelial ovarian carcinoma

Cite and Share

M. Gultekin,K. Diribas,E. Buru,P. Dursun,K. Yuce,A. Ayhan. Interval debulking in epithelial ovarian carcinomas: the past, present and the future. European Journal of Gynaecological Oncology. 2008. 29(3);242-245.

URL:

https://www.ejgo.net/articles/10.12892/ejgo200803242

References

[1] Huober J., Meyer A., Wagner U., Wallwiener D.: “The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer”. J. Cancer Res. Clin. Oncol., 2002, 128, 153.

[2] Chan J.K., Manuel M., Osann K., Cheung M.K.: “Progress and trends in ovarian cancer survival over the last 15 years”. Abstract on Annual Meetings on Women’s Cancer. Society of Gynecologic Oncology, 2005.

[3] Skirnisdottir I., Sorbe B.: “Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-Stages IIIIV) epithelial ovarian carcinoma”. Int. J. Oncol., 2007, 30, 727.

[4] Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C. et al.: “The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with Stages IIIC-IV epithelial ovarian cancer”. Gynecol. Oncol., 2006, 103, 1083.

[5] Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., Podratz K.C., Cliby W.A.: “Aggressive surgical effort and improved survival in advanced-stage ovarian cancer”. Obstet. Gynecol., 2006, 107, 77.

[6] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis”. J. Clin. Oncol., 2002, 20, 1248.

[7] Hunter R.W., Alexander N.D., Soutter W.P.: “Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?”. Am. J. Obstet. Gynecol., 1992, 166, 504.

[8] Covens A.L.: “A critique of surgical cytoreduction in advanced ovarian cancer”. Gynecol. Oncol., 2000, 78, 269.

[9] Morice P., Brehier-Ollive D., Rey A., Atallah D., Lhomme C., Pautier P. et al.: “Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study”. Ann. Oncol., 2003, 14, 74.

[10] Vergote I., de Wever I., Tjalma W., Van Gramberen M., Decloedt J., Van Dam P.: “Interval debulking surgery: an alternative for primary surgical debulking?”. Semin. Surg. Oncol., 2000, 19, 49.

[11] Gallo A., Frigerio L.: “Neoadjuvant chemotherapy and surgical considerations in ovarian cancer”. Curr. Opin. Obstet. Gynecol., 2003, 15, 25.

[12] Pecorelli S., Odicino F., Favalli G.: “Interval debulking surgery in advanced epithelial ovarian cancer”. Best. Pract. Res. Clin. Obstet. Gynaecol., 2002, 16, 573.

[13] Schwartz P.E.: “Neoadjuvant chemotherapy for the management of ovarian cancer”. Best. Pract. Res. Clin. Obstet. Gynaecol., 2002, 16, 585.

[14] Redman C.W., Warwick J., Luesley D.M., Varma R., Lawton F.G., Blackledge G.R.: “Intervention debulking surgery in advanced epithelial ovarian cancer”. Br. J. Obstet. Gynaecol., 1994, 101, 142.

[15] van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G. et al.: “The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer”. N. Engl. J. Med., 1995, 332, 629.

[16] Kehoe S., Shafi M., Luesley D.: “Interval cytoreduction in ovarian cancer (letter)”. N. Engl. J. Med., 1995, 333, 254.

[17] Neijt J.P.: “Interval cytoreduction in ovarian cancer (letter)”. N. Engl. J. Med., 1995, 333, 254.

[18] Cannistra S.A.: “Interval cytoreduction in ovarian cancer (letter)”. N. Engl. J. Med., 1995, 333, 255.

Current Issue

Vol., Issue , Invalid date

Table of contents
All Issues

Submit to EJGO Review for EJGO Edit a Special Issue

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top